1. Peptide vaccinations elicited strong immune responses that were reboosted by anti-PD1 therapy in a patient with myxofibrosarcoma.
- Author
-
Tsukahara T, Watanabe K, Murata K, Takahashi A, Mizushima E, Shibayama Y, Kameshima H, Hatae R, Ohno Y, Kawahara R, Murai A, Nakatsugawa M, Kubo T, Kanaseki T, Hirohashi Y, Terui T, Asanuma H, Hasegawa T, Sato N, and Torigoe T
- Subjects
- Biomarkers, Tumor, Cancer Vaccines administration & dosage, Combined Modality Therapy, Fibroma diagnosis, Fibrosarcoma diagnosis, Humans, Immunohistochemistry, Immunophenotyping, Male, Middle Aged, Positron Emission Tomography Computed Tomography, Tomography, X-Ray Computed, Cancer Vaccines immunology, Fibroma immunology, Fibroma therapy, Fibrosarcoma immunology, Fibrosarcoma therapy, Immunization, Secondary, Peptides immunology, Programmed Cell Death 1 Receptor antagonists & inhibitors
- Abstract
Peptide-based immunotherapy does not usually elicit strong immunological and clinical responses in patients with end-stage cancer, including sarcoma. Here we report a myxofibrosarcoma patient who showed a strong clinical response to peptide vaccinations and whose immune responses were reboosted by anti-PD1 therapy combined with peptide vaccinations. The 46-year-old man showed a strong response to the peptide vaccinations (papillomavirus binding factor peptide, survivin-2B peptide, incomplete Freund's adjuvant, and polyethylene glycol-conjugated interferon-alpha 2a) and subsequent wide necrosis and massive infiltration of CD8+ T cells in a recurrent tumor. The patient's immune responses weakened after surgical resection; however, they were reboosted following the administration of nivolumab combined with peptide vaccinations. Thus, anti-PD1 therapy combined with peptide vaccinations might be beneficial, as suggested by the observations in this sarcoma patient.
- Published
- 2020
- Full Text
- View/download PDF